drugset / Trial / NCT01680796
Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label phase I study in which dovitinib is given in combination with bortezomib and dexamethasone. Dovitinib dose escalation is planned in order to determine its maximum tolerated dose when given in this combination.
Timeline
- Start
- 2013-02
- Primary completion
- 2013-02
- Completion
- 2013-02
Outcome
Outcome not reported
Stopped: “The target drug, dovitinib, failed as a single agent in prior studies in patients with heavily treated multiple myeloma.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dovitinib | Small molecule | 200 mg | Oral |
| Subject | Dovitinib | Small molecule | 300 mg | Oral |
| Subject | Dovitinib | Small molecule | 400 mg | Oral |
| Subject | Dovitinib | Small molecule | 500 mg | Oral |
| Background | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Background | Bortezomib | Small molecule | 1.6 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 20 mg | Oral |